As of 2025-07-20, the EV/EBITDA ratio of Bridge Biotherapeutics Inc (288330.KQ) is -8.08. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 288330.KQ's latest enterprise value is 142,122.89 mil KRW. 288330.KQ's TTM EBITDA according to its financial statements is -17,595.02 mil KRW. Dividing these 2 quantities gives us the above 288330.KQ EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.9x - 18.6x | 14.2x |
| Forward P/E multiples | 13.7x - 23.4x | 18.6x |
| Fair Price | (4,578.65) - (6,223.87) | (5,482.17) |
| Upside | -265.3% - -324.7% | -297.9% |
| Date | EV/EBITDA |
| 2025-07-17 | -8.08 |
| 2025-07-16 | -8.46 |
| 2025-07-15 | -8.58 |
| 2025-07-14 | -8.79 |
| 2025-07-11 | -8.69 |
| 2025-07-10 | -8.82 |
| 2025-07-09 | -8.83 |
| 2025-07-08 | -7.41 |
| 2025-07-07 | -7.40 |
| 2025-07-04 | -9.71 |
| 2025-07-03 | -9.95 |
| 2025-07-01 | -9.99 |
| 2025-06-30 | -7.90 |
| 2025-06-26 | -7.81 |
| 2025-06-25 | -5.99 |
| 2025-06-24 | -4.58 |
| 2025-06-23 | -3.49 |
| 2025-06-20 | -2.66 |
| 2025-06-19 | -2.18 |
| 2025-06-18 | -2.32 |
| 2025-06-17 | -2.05 |
| 2025-06-16 | -1.88 |
| 2025-06-13 | -1.92 |
| 2025-06-12 | -1.98 |
| 2025-06-11 | -2.08 |
| 2025-06-10 | -2.08 |
| 2025-06-09 | -2.08 |
| 2025-06-05 | -2.03 |
| 2025-06-04 | -2.04 |
| 2025-06-02 | -2.04 |
| 2025-05-30 | -2.03 |
| 2025-05-29 | -2.09 |
| 2025-05-28 | -2.01 |
| 2025-05-27 | -2.04 |
| 2025-05-26 | -2.12 |
| 2025-05-23 | -1.97 |
| 2025-05-22 | -1.98 |
| 2025-05-21 | -2.06 |
| 2025-05-20 | -2.15 |
| 2025-05-19 | -1.99 |
| 2025-05-16 | -2.02 |
| 2025-05-15 | -2.02 |
| 2025-05-14 | -2.15 |
| 2025-05-13 | -2.01 |
| 2025-05-12 | -2.15 |
| 2025-05-09 | -2.25 |
| 2025-05-08 | -2.45 |
| 2025-05-07 | -2.40 |
| 2025-05-02 | -2.45 |
| 2025-04-30 | -2.51 |